



News Release

September 7, 2023
Maruho Co., Ltd.

Maruho and Journey Medical Corporation Enter into an Exclusive License Agreement for a Hyperhidrosis Treatment (Topical Anticholinergic Agent) in Asia

Osaka, Japan, September 7, 2023 – Maruho Co., Ltd. (“Maruho”; Head Office: Osaka, Japan, President and CEO: Atsushi Sugita) announced that on August 31, 2023 it entered into an exclusive license agreement with Journey Medical Corporation (“Journey Medical”; Head Office: Scottsdale, Arizona, U.S., President and CEO: Claude Maraoui) for hyperhidrosis treatment glycopyrronium tosilate hydrate (JAN), hereinafter referred to as "the product"), in South Korea, Taiwan, Hong-Kong, Macau, and the 10 ASEAN member states¹.

Under the terms of the agreement, Journey Medical grants Maruho an exclusive license to develop, manufacture, and market the product in Korea, Taiwan, Hong Kong, Macau, and the 10 ASEAN member states.

Maruho will pay Journey Medical an upfront payment and milestone payments based on future sales progress. Maruho will also pay royalties based on sales after the product is marketed.

The product reduces sweat production by blocking the activation of acetylcholine receptors in sweat glands.

In Japan, Maruho entered a license agreement with Dermira² in September 2016 to obtain an exclusive license to develop, manufacture, and market the product. In January 2022, Maruho obtained manufacturing and marketing approval for the indication of primary axillary hyperhidrosis. In May 2022, Maruho launched the product under the brand name "Rapifort® Wipes 2.5%".

Specializing in dermatology, Maruho hopes to contribute to improving the quality of life of patients suffering from primary axillary hyperhidrosis in the countries and regions covered by this agreement.

Note

The information contained in this news release in regard to pharmaceutical and developmental products is not intended for the purpose of promotion, advertising or medical advice.

1. Thailand, Indonesia, Malaysia, Philippines, Singapore, Vietnam, Brunei, Cambodia, Myanmar and Laos.
2. Currently, Journey Medical owns the rights to the product under the Asset Purchase Agreement between Dermira and Journey Medical dated March 31, 2021.



Reference information

Maruho enters a License Agreement with Dermira for Hyperhidrosis treatment agent DRM04
https://www.maruho.co.jp/english/information/20160921_pr_eng.pdf

Maruho Receives Manufacturing and Marketing Approval for Primary Axillary Hyperhidrosis Treatment "Rapifort Wipes 2.5%" in Japan
<https://www.maruho.co.jp/english/information/20220120.html>

Maruho Launches Primary Axillary Hyperhidrosis Treatment "Rapifort Wipes 2.5%" in Japan
<https://www.maruho.co.jp/english/information/20220523.html>

About Journey Medical Corporation

Journey Medical is a pharmaceutical company located in Arizona, U.S. Founded in 2014, the company primarily focuses on products for the treatment of dermatological conditions.

For more information, please visit <https://www.journeymedicalcorp.com/>

About Maruho

Maruho Co., Ltd. has its head office in Osaka and leads Japan in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,547 employees (as of the end of September 2022), and net sales were approximately 85.67 billion yen in its fiscal year ended September 30, 2022. With the mission "More smiles, brighter life for you.", Maruho aims to help realize a society where everyone can live with a smile.

For more information, please visit <https://www.maruho.co.jp/english/>

Contact Information:

Maruho Co., Ltd.

Corporate Planning Dept., Public Relations Group

Tel: +81-(0)6-6371-8831

Email: kouhou@mii.maruho.co.jp